CoChat

Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review

Open access
Dziewierz, Artur, Siudak, Zbigniew · 2026 · Nutrients

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index; 108 of the 144 sources its claims cite were checked for support.

Abstract

Adherence and Adherence/Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review. Global persistence varies widely: from approximately 75–80% at 12 months in reimbursed T2DM cohorts to below 10% in obesity-focused or high out-of-pocket-cost settings; in several cohorts, persistence falls below 15% by 24 months. The primary drivers are gastrointestinal intolerance and economic barriers.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes international real-world evidence showing that GLP-1 receptor agonist persistence is highly variable and substantially below clinical-trial retention, driven mainly by gastrointestinal intolerance and economic barriers. It proposes integrating medical nutrition therapy and structured lifestyle/behavioral support into routine GLP-1 care, while acknowledging that most supporting evidence is extrapolated rather than derived from GLP-1-specific randomized trials.

Key findings

  • Real-world persistence ranged from approximately 75–80% at 12 months in reimbursed T2DM cohorts (Sweden ~76.4%; Denmark ~78.8%) to below 10% in obesity-focused or high out-of-pocket settings (Poland 6.6% long-term persistence; Colombia 0.2% at 12 months); U.S. company-published data reported 8.1% persistence at 3 years, and UK data reported ~54.8% at 12 months and ~35.3% at 24 months.
  • GI intolerance and economic barriers were the primary drivers; in STEP UP, GI adverse events occurred in ~71% with semaglutide 7.2 mg vs 61% with 2.4 mg and 43% with placebo, and a cross-sectional survey found patients most often cited nausea (64.4%) and vomiting (45.4%), while physicians most often cited inadequate glycemic control (45.6%) and nausea/vomiting (43.8%).
  • The proposed nutritional framework includes protein targets of 1.2–1.5 g/kg/day in chronic illness and up to ~1.6 g/kg/day during active weight loss, resistance training 2–3 times weekly, nutrient-dense lower-volume meals, and micronutrient screening; U.S. Medicare MNT coverage excludes obesity without T2DM or CKD.
  • Cardiovascular benefit may be partly independent of weight loss: SELECT showed a 20% MACE reduction, and a prespecified analysis suggested waist-circumference reduction mediated only approximately one-third of the treatment effect.

Methods

  • Narrative review using PubMed as the primary database, supplemented by Embase, Google Scholar, and hand-searching; English-language publications from inception through 31 January 2026 in adults ≥19 years. The primary PubMed search identified 5523 records, reduced to 3935 human studies and 2138 adult studies, with 87 publications included in the final synthesis.
  • Eligible sources included RCTs, prospective/retrospective cohorts, insurance claims and pharmacy benefit analyses, national registry studies, systematic reviews/meta-analyses, and consensus documents; exclusions included non-English publications, pediatric-only studies, single case reports unless illustrating a novel mechanistic concept, and non-peer-reviewed grey literature except labeled company-reported real-world evidence.
  • No formal risk-of-bias assessment, GRADE rating, or meta-analytic synthesis was performed; studies were selected by topical relevance, prioritizing landmark RCTs, large real-world cohort/claims analyses, and recent 2023–2026 primary publications.

Limitations

  • Stated: as a narrative rather than systematic review, selection and synthesis are subject to selection bias; no formal risk-of-bias assessment, GRADE rating, or meta-analysis was performed. Persistence definitions, allowable gap thresholds (60 vs 90 days), follow-up durations, and data sources differ across studies, precluding direct quantitative cross-cohort comparison, and the evidence base is predominantly from high-income settings, limiting generalizability to low- and middle-income countries.
  • Stated: many nutritional and behavioral recommendations are extrapolated from related populations or expert consensus rather than GLP-1-specific randomized trials; direct randomized evidence for integrated MNT/behavioral support improving persistence is limited. The microbiota evidence comes from a single 60-day RCT in 25 adults, the neuroimaging evidence is a single-patient case, and the dietary volume/gastric-stasis mechanism has not been tested in randomized dietary-modification trials within GLP-1 RA cohorts.
  • Evident: the review includes company-published, non-peer-reviewed real-world data (e.g., Prime Therapeutics, Omada Health), and the Omada cohort was self-selected, digitally engaged, and commercially insured; the AI-driven lifestyle RCT was conducted in a non-GLP-1-using population, and several cited sources are cross-sectional surveys or single-case observations, limiting causal inference.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu18111761

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Flow of literature identification and selection for the narrative review.
Figure 1 Flow of literature identification and selection for the narrative review.CC BY · PubMed Central
Figure 2 Proposed integrated care framework for closing the GLP-1 RA persistence gap. The framework comprises six strategic domains targeting the principal physiological, behavioral, and systemic drivers of treatment discontinuation, with each domain specifying a target mechanism and an evidence-informed or proposed support strategy. Solid borders denote evidence-informed strategies supported by primary trial evidence or aligned international consensus, even if extrapolated to the GLP-1 RA context. Dashed borders denote proposed strategies that are physiologically plausible and supported by mechanistic reasoning or preliminary data but await confirmation in GLP-1 RA-specific randomized trials; Section 6.6 provides the full strength-of-evidence hierarchy. The framework presents the conceptual scope of integrated care; the temporal sequence in which these components are operationalized across the patient journey is presented separately in Figure 3. AI, artificial intelligence; CBT, cognitive behavioral therapy; DPP, Diabetes Prevention Program; FDA, Food and Drug Administration; GLP-1 RA, glucagon-like peptide-1 receptor agonist; GI, gastrointestinal; MACE, major adverse cardiovascular events; MNT, Medical Nutrition Therapy; RCT, randomized controlled trial; RDN, registered dietitian nutritionist; SOD, superoxide dismutase; WHO, World Health Organization.
Figure 2 Proposed integrated care framework for closing the GLP-1 RA persistence gap. The framework comprises six strategic domains targeting the principal physiological, behavioral, and systemic drivers of treatment discontinuation, with each domain specifying a target mechanism and an evidence-informed or proposed support strategy. Solid borders denote evidence-informed strategies supported by primary trial evidence or aligned international consensus, even if extrapolated to the GLP-1 RA context. Dashed borders denote proposed strategies that are physiologically plausible and supported by mechanistic reasoning or preliminary data but await confirmation in GLP-1 RA-specific randomized trials; Section 6.6 provides the full strength-of-evidence hierarchy. The framework presents the conceptual scope of integrated care; the temporal sequence in which these components are operationalized across the patient journey is presented separately in Figure 3. AI, artificial intelligence; CBT, cognitive behavioral therapy; DPP, Diabetes Prevention Program; FDA, Food and Drug Administration; GLP-1 RA, glucagon-like peptide-1 receptor agonist; GI, gastrointestinal; MACE, major adverse cardiovascular events; MNT, Medical Nutrition Therapy; RCT, randomized controlled trial; RDN, registered dietitian nutritionist; SOD, superoxide dismutase; WHO, World Health Organization.CC BY · PubMed Central
Figure 3 Phase-based clinical pathway for integrated GLP-1 RA care. Each of four sequential phases-from pre-initiation assessment through long-term maintenance or de-escalation-specifies the principal nutritional, behavioral, and clinical actions required at that stage. The pathway operationalizes the components of integrated care (Figure 2) into a temporally sequenced implementation guide for use in routine clinical practice. BIA, bioelectrical impedance analysis; CKD, chronic kidney disease; DXA, dual-energy X-ray absorptiometry; GI, gastrointestinal; HbA1c, glycated hemoglobin.
Figure 3 Phase-based clinical pathway for integrated GLP-1 RA care. Each of four sequential phases-from pre-initiation assessment through long-term maintenance or de-escalation-specifies the principal nutritional, behavioral, and clinical actions required at that stage. The pathway operationalizes the components of integrated care (Figure 2) into a temporally sequenced implementation guide for use in routine clinical practice. BIA, bioelectrical impedance analysis; CKD, chronic kidney disease; DXA, dual-energy X-ray absorptiometry; GI, gastrointestinal; HbA1c, glycated hemoglobin.CC BY · PubMed Central

Verification

Claims the paper makes

65 Valid · 8 Not valid · 25 Not checked · 49 Own results and interpretations

56 more claims · 26 with their cited sources checked

Create a free account to see all 147 claims and to verify the 5 references still open.

See all claims — free account
  • It may state two separate claims as one. 74
  • Probably not a substantial claim. 21
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Research works printed but not linked: 1

  1. (2005). Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate, National Academies Press.

Cited by

See all 3

Metadata

Authors
Dziewierz, A., & Siudak, Z.
Affiliations
  • Jagiellonian University (PL)
  • Jan Kochanowski University (PL)
Corresponding author
Siudak, Zbigniew
Venue
Nutrients
Publisher
MDPI AG
Published
2026-05-30
Volume
18
Issue
11
Pages
1761
ISSN
2072-6643 (ISSN-L)
OpenAlex
W7163024474
Cited by
3
References
74
Citations by year
2026: 3
FWCI
3.18
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Keywords
GLP-1 receptor agonists, treatment persistence, medication adherence, type 2 diabetes, obesity, medical nutrition therapy, gastrointestinal intolerance, protein intake, lean mass loss, gastric emptying, cost barriers, integrated care, real-world effectiveness
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Adherence Interventions, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Life Style, Obesity, Weight Loss, Nutrition Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.